A group of Maryland senators recently filed a bill that would create a state fund that could be used to provide free access to psychedelics like psilocybin, MDMA and ketamine for military veterans suffering from post-traumatic stress disorder (PTSD), while also supporting research into their therapeutic potential.
The legislation, sponsored by Sen. Sarah Elfreth (D), would establish what’s being called the Post-Traumatic Stress Disorder Alternative Therapies Fund. In addition to funding research into psychedelics through the state Department of Health, money would also be appropriated under the bill to provide “cost-free access to alternative therapies” for the target community.
Further, it says that regulators must periodically “consult with the Department of Veterans Affairs, the Johns Hopkins University, the University of Maryland, Sheppard Pratt, and Walter Reed National Military Medical Center” on the use of entheogenic substances for PTSD.
There are also reporting requirements that could set the stage for future legislation on providing regulated access to psychedelics for therapeutic use.
Marijuana Moment is already tracking more than 1,000 cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments.
Learn more about our marijuana bill tracker and become a supporter on Patreon to get access.
The Maryland Department of Health would need to first submit a report to the governor and legislation with “initial findings and recommendations” by December 1, 2022. Two years later, there would be another deadline for findings and recommendations that are based on studies that were specifically funded through the PTSD fund.
The report must include “any findings regarding the efficacy of alternative therapies as treatment for post–traumatic stress disorder,” as well as “recommendations on budgetary, legislative, or regulatory changes to expand access to alternative therapies for veterans with post–traumatic stress disorder,” the bill text says.
The bill already has nine senators as cosponsors, and it’s scheduled to receive a hearing in the Budget and Taxation Committee on March 2.
The proposal is the latest example of how psychedelics reform is expanding into state legislatures following several successful local campaigns to decriminalize the plants and fungi.
Just last week, a Utah House committee approved a bill that would similarly create a task force to study and make recommendations on the therapeutic potential of psychedelic drugs and possible regulations for their lawful use.
Two Republican Oklahoma lawmakers recently filed bills meant to promote research into the therapeutic potential of psilocybin, and one of the measures would further decriminalize low-level possession of the psychedelic.
A Republican Missouri lawmaker introduced a bill last month to give residents with serious illnesses legal access to a range of psychedelic drugs like psilocybin, ibogaine and LSD through an expanded version of the state’s existing right-to-try law.
A bill to decriminalize a wide array of psychedelics in Virginia was taken up by a House of Delegates panel last month, only to be pushed off until 2023. A separate Senate proposal to decriminalize psilocybin alone was later defeated in a key committee.
California Sen. Scott Wiener (D) told Marijuana Moment in a recent interview that his bill to legalize psychedelics possession stands a 50/50 chance of reaching the governor’s desk this year. It already cleared the full Senate and two Assembly committees during the first half of the two-year session.
Washington State lawmakers also introduced legislation last month that would legalize what the bill calls “supported psilocybin experiences” by adults 21 and older.
New Hampshire lawmakers filed measures to decriminalize psilocybin and all drugs.
Last year, the governor of Connecticut signed legislation that includes language requiring the state to carry out a study into the therapeutic potential of psilocybin mushrooms.
Similar legislation was also enacted by the Texas legislature, requiring the state to study the medical risks and benefits of psilocybin, MDMA and ketamine for military veterans in partnership with Baylor College of Medicine and a military-focused medical center.
Activists in Colorado recently filed revised versions of 2022 ballot initiatives to similarly legalize psilocybin and establish “healing centers” in the state. A competing campaign filed a different psychedelics legalization last month.
Michigan activists filed a statewide ballot initiative last week that would legalize possessing, cultivating and sharing psychedelics and set up a system for their therapeutic and spiritual use.
A pair of Michigan senators also introduced a bill in September to legalize the possession, cultivation and delivery of an array of plant- and fungi-derived psychedelics like psilocybin and mescaline.
At the congressional level, bipartisan lawmakers sent a letter to the Drug Enforcement Administration (DEA) last month, urging that the agency allow terminally ill patients to use psilocybin as an investigational treatment without the fear of federal prosecution.